Corvus Pharmaceuticals Financial Statements 2014-2023 | CRVS

Revenue

Cost Of Goods Sold

Gross Profit

Research And Development Expenses

$16.526

$24.468

$29.115

$31.83

$37.975

$38.586

$46.305

$29.356

$11.352

SG&A Expenses

$6.881

$8.097

$9.515

$11.93

$10.879

$10.636

$10.219

$7.62

$2.418

Other Operating Income Or Expenses

Operating Expenses

Operating Income

$-23.407

$-32.565

$-38.63

$-43.76

$-48.854

$-49.222

$-56.524

$-36.976

$-13.77

Total Non-Operating Income/Expense

$-3.622

$-8.742

$-4.611

$37.765

$2.182

$2.283

$0.861

$0.601

$-17.565

Pre-Tax Income

$-27.029

$-41.307

$-43.241

$-5.995

$-46.672

$-46.939

$-55.663

$-36.375

$-31.335

Income Taxes

Income After Taxes

$-27.029

$-41.307

$-43.241

$-5.995

$-46.672

$-46.939

$-55.663

$-36.375

$-31.335

Other Income

Income From Continuous Operations

$-27.029

$-41.307

$-43.241

$-5.995

$-46.672

$-46.939

$-55.663

$-36.375

$-31.335

Income From Discontinued Operations

Net Income

$-27.029

$-41.307

$-43.241

$-5.995

$-46.672

$-46.939

$-55.663

$-36.375

$-31.335

EBITDA

$-24.15

$-32.368

$-37.931

$-42.974

$-48.755

$-48.983

$-55.877

$-35.734

$-13.663

EBIT

$-23.407

$-32.565

$-38.63

$-43.76

$-48.854

$-49.222

$-56.524

$-36.976

$-13.77

Basic Shares Outstanding

Shares Outstanding

Basic EPS

$-0.56

$-0.89

$-1.03

$-0.20

$-1.59

$-1.71

$-2.72

$-2.36

$-83.86

EPS - Earnings Per Share

$-0.56

$-0.89

$-1.03

$-0.20

$-1.59

$-1.71

$-2.72

$-2.36

$-83.86